Rifabutin: Is it useful in the treatment of multidrug-resistant tuberculosis?

Affiliations

¹ Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University, London, UK; Division of Infection, Royal London Hospital, Barts Health NHS Trust, London, UK.
² World Health Organization Collaborating Centre for Tuberculosis and Lung Diseases, Maugeri Care and Research Institute, Tradate, Italy; Public Health Consulting Group, Lugano, Switzerland.
³ World Health Organization Collaborating Centre for Tuberculosis and Lung Diseases, Maugeri Care and Research Institute, Tradate, Italy.
⁴ World Health Organization Collaborating Centre for Tuberculosis and Lung Diseases, Maugeri Care and Research Institute, Tradate, Italy. Electronic address: giovannibattista.migliori@icsmaugeri.it.

Free article

Editorial

S Tiberi et al. Int J Infect Dis. 2017 Dec.

Free article

. 2017 Dec:65:133-134.

doi: 10.1016/j.ijid.2017.10.019. Epub 2017 Nov 6.

¹ Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University, London, UK; Division of Infection, Royal London Hospital, Barts Health NHS Trust, London, UK.
² World Health Organization Collaborating Centre for Tuberculosis and Lung Diseases, Maugeri Care and Research Institute, Tradate, Italy; Public Health Consulting Group, Lugano, Switzerland.
³ World Health Organization Collaborating Centre for Tuberculosis and Lung Diseases, Maugeri Care and Research Institute, Tradate, Italy.
⁴ World Health Organization Collaborating Centre for Tuberculosis and Lung Diseases, Maugeri Care and Research Institute, Tradate, Italy. Electronic address: giovannibattista.migliori@icsmaugeri.it.

No abstract available

Comment on

Treatment outcomes of rifabutin-containing regimens for rifabutin-sensitive multidrug-resistant pulmonary tuberculosis.
Lee H, Ahn S, Hwang NY, Jeon K, Kwon OJ, Huh HJ, Lee NY, Koh WJ. Lee H, et al. Int J Infect Dis. 2017 Dec;65:135-141. doi: 10.1016/j.ijid.2017.10.013. Int J Infect Dis. 2017. PMID: 29224631